Why This Analyst Upgraded Shares Of Cardiome To 'Speculative Buy'; Stock Skyrockets In Pre-Market

By: via Benzinga
Mackie Research has upgraded CARDIOME PHARMA CORP (NASDAQ: CRME) to Speculative Buy from Hold on its recent licensing of Xydalba ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.